When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials - 27/09/17

C. Michael Gibson, MS, MD ^{a, ⁎} , Samuel Z. Goldhaber, MD ^b, Alexander T. Cohen, MD ^c, Tarek Nafee, MD ^a, Adrian F. Hernandez, MD ^d, Russell Hull, MBBS ^e, Serge Korjian, MD ^a, Yazan Daaboul, MD ^a, Gerald Chi, MD ^a, Megan Yee, MPH ^a, Robert A. Harrington, MD ^f

^a PERFUSE Study Group, Cardiovascular Division, Departments of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 

^b Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 

^c Guy's and St Thomas' Hospitals, London, United Kingdom 

^d Duke University and Duke Clinical Research Institute, Durham, NC 

^e Division of Cardiology, R.A.H Faculty of Medicine, University of Calgary, Alberta, Canada 

^f Department of Medicine, Stanford University, Stanford, CA 

^⁎Reprint requests: C. Michael Gibson, MS, MD, PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Suite OV-540, Boston, MA 02215.PERFUSE Study Group, Cardiovascular Division, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical School330 Brookline Ave, Suite OV-540BostonMA02215

Le texte complet de cet article est disponible en PDF.